As developing
Asian markets increasingly clamor for advanced
medical care, foreign multinationals are seeing
accelerating sales growth in Asian health sectors.
As opportunities abound in the CRO, pharmaceutical,
and medical devices sector, international pharma
and medical device manufacturers will continue
to invest in overseas expansion in Asia.
BDA has worked for major healthcare
companies from North America, Europe and Asia
on a wide range of strategic projects and corporate
finance transactions, such as:
Advised on
acquisition of life sciences target in China
for Millipore
Advised on
a health products acquisition in Japan for
Kimberly-Clark
Identification
of targets in the Chinese pharmaceutical /biopharmaceutical
sector for Rohm
and Haas
Search and
advisor on proposed acquisition of Chinese
pharmaceutical company for Solvay
Adviser on
investment in the Japanese HRT sector for
Teikoku
Hormone
